Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

11.8K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
11.8K
What is Cancer?02:12

What is Cancer?

10.6K
Cells and tissues must meticulously coordinate their activities for the normal functioning of the human body. Therefore, they exhibit socially responsible behavior - resting, growing, dividing, differentiating, or dying - for the organism’s benefit. Cancer arises when cells divide uncontrollably and invade other tissues or organs.
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
10.6K
Tumor Progression02:07

Tumor Progression

6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and Internal Validation of a Machine Learning-Based Classification Model for Identifying Cognitive Frailty in Older Inpatients with Type 2 Diabetes Mellitus.

Clinical interventions in aging·2026
Same author

Two Fatty Acids From Host Plant Leaves Are Attractive to Soritia leptatina Adults.

Journal of chemical ecology·2026
Same author

The IMMUNO-BIOMAP trial in NSCLC: An adaptive multimodal framework for biomarker-guided care.

Cell reports. Medicine·2026
Same author

Systems-level analysis identifies IRF6 as an inhibitor of epithelial-mesenchymal transition.

Journal of biological engineering·2026
Same author

Upfront low-dose biosimilar rituximab as first biologic therapy after triple csDMARD failure in seropositive rheumatoid arthritis: a prospective real-world strategy study.

Clinical rheumatology·2026
Same author

AI-Driven Design of High Affinity Biomolecule-Drug Conjugates for Gynecological Cancer Therapy: An Up-to-Date Narrative Review.

Cancers·2026

Related Experiment Video

Updated: Jun 17, 2025

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.4K

Phenotypic Plasticity and Cancer: A System Biology Perspective.

Ayalur Raghu Subbalakshmi1, Sravani Ramisetty1, Atish Mohanty1

  • 1Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA 91010, USA.

Journal of Clinical Medicine
|August 10, 2024
PubMed
Summary
This summary is machine-generated.

Cancer cells exhibit hybrid epithelial/mesenchymal (E/M) phenotypes, crucial for metastasis and drug resistance. A systems biology approach is key to understanding and targeting this plasticity for novel cancer therapeutics.

Keywords:
circulating tumor cellsepithelial mesenchymal transitionhybrid E/M cellsplasticity

More Related Videos

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation
10:24

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation

Published on: September 19, 2019

6.4K
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

755

Related Experiment Videos

Last Updated: Jun 17, 2025

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.4K
Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation
10:24

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation

Published on: September 19, 2019

6.4K
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

755

Area of Science:

  • Oncology
  • Cell Biology
  • Systems Biology

Background:

  • Epithelial-to-mesenchymal transition (EMT) drives phenotypic plasticity in development, wound healing, and diseases like cancer metastasis and fibrosis.
  • Cancer stem cell (CSC) transitions also contribute to plasticity with metastatic implications.
  • Phenotypic states are not binary; cancer cells adopt hybrid epithelial/mesenchymal (E/M) phenotypes.

Purpose of the Study:

  • To explore the role of hybrid E/M phenotypes in cancer progression and therapeutic resistance.
  • To advocate for a systems biology perspective in understanding cancer cell plasticity.
  • To highlight the potential of interdisciplinary 'Team Medicine' in identifying novel cancer therapeutics.

Main Methods:

  • Review and discussion of existing literature on EMT and cancer stem cells.
  • Conceptual framework integrating systems biology and team medicine approaches.
  • Analysis of the implications of hybrid E/M phenotypes in cancer.

Main Results:

  • Hybrid E/M phenotypes are integral to tumor initiation, metastasis, and disease progression.
  • These hybrid phenotypes significantly contribute to therapeutic resistance in various cancers.
  • Phenotypic plasticity, including hybrid states, presents a complex challenge in cancer treatment.

Conclusions:

  • A systems biology approach, incorporating interdisciplinary expertise, is essential for advancing our understanding of cancer cell plasticity.
  • Targeting phenotypic plasticity, particularly hybrid E/M states, offers promising avenues for novel therapeutic strategies.
  • Team Medicine is crucial for developing comprehensive strategies to combat cancer metastasis and resistance.